FDA POLICY COSTS
May 15 - This week the FDA turned down two new experimental immunotherapy treatments for prostate cancer and a rare form of children's bone cancer because they were 1% short of the required level of performance. FDA rules require 95% effectiveness and the human trials were producing results of only 94%. Check out the editorial in the Monday, May 14th WALL STREET JOURNAL by Dr. Mark Thornton. Once again the bureaucrats running the FDA put rules by tiny minds ahead of the lives of real people. No wonder so many Americans have to go to Mexico, Europe or Asia to get the treatments they need today.